Avastin (with capecitabine) for Metastatic Colorectal Cancer - Details


( Last Updated : November 13, 2015)
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
Metastatic Colorectal Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Avastin (with capecitabine)
Project Line:
Reimbursement Review
Project Number:
PC0055-000
NOC Date:

Details


Strength:
25 mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy
Review Status:
Complete
Sponsor:
Cancer Care Ontario Gastrointestinal Disease Site Group
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
Check-point meeting (target date):
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
In combination with capecitabine, for the first-line treatment of advanced or metastatic colorectal cancer (CRC) for patients who are not suitable for oxaliplatin or irinotecan-based therapy
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.